Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Schmiegelow, Michelle D ^a   Pedersen, Ole D ^b   Køber, Lars ^c   Seibæk, Marie ^d   Abildstrøm, Steen Z ^e   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOFETILIDE; PLACEBO; ANTIARRHYTHMIC AGENT; PHENETHYLAMINE DERIVATIVE; SULFONAMIDE;

ACUTE HEART INFARCTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; CHI SQUARE DISTRIBUTION; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DENMARK; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PHENETHYLAMINES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 79955842670     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-19     Document Type: Article

References (18)

1. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005, 26:350-356. 10.1093/eurheartj/ehi064, 15618041.
2. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005, 26:1303-1308. 10.1093/eurheartj/ehi166, 15767288.
3. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-354.
4. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999, 20:748-754. 10.1053/euhj.1998.1352, 10329066.
5. Kalra L, Lip GY. Antithrombotic treatment in atrial fibrillation. Heart 2007, 93:39-44. 10.1136/hrt.2006.099911, 1861321, 16952971.
6. Chung I, Lip GY. Antithrombotic therapy for congestive heart failure. Int J Clin Pract 2006, 60:36-47.
7. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009, 119:606-618. 10.1161/CIRCULATIONAHA.108.825380, 2635942, 19188521.
8. Group TDS. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol 1997, 20:704-710. 10.1002/clc.4960200808, 9259163.
9. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341:857-865. 10.1056/NEJM199909163411201, 10486417.
10. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000, 356:2052-2058. 10.1016/S0140-6736(00)03402-4, 11145491.
11. Pedersen OD, Sondergaard P, Nielsen T, Nielsen SJ, Nielsen ES, Falstie-Jensen N, Nielsen I, Kober L, Burchardt H, Seibaek M, Torp-Pedersen C. Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure. Eur Heart J 2006, 27:2866-2870. 10.1093/eurheartj/ehl359, 17101637.
12. Declaration of Helsinki (1964). BMJ 1996, 313:1448a-1449.
13. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046. 10.1161/01.CIR.0000140263.20897.42, 15313941.
14. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den Berg MP, van Veldhuisen DJ. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000, 21:1238-1245. 10.1053/euhj.1999.2107, 10924313.
15. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548-557. 10.1016/j.ahj.2004.09.033, 15864246.
16. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001, 86:527-532. 10.1136/heart.86.5.527, 1729969, 11602545.
17. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677. 10.1056/NEJMoa0708789, 18565859.
18. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678. 10.1056/NEJMoa0803778, 19213680.